Ali Behbahani sold $781k of CRSP
director at CRISPR Therapeutics AG. 13,679 shares at an average of $57.09, traded Sep 17, 2026, filed Sep 21, 2026.
Score components
- +15RoleDirector
- +22Trade size$781k at market
- +10Share of holdings soldSold 45% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-396944, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | MOption exercise Common Shares | +30,000 | $14.00 | $420k | 30,316 | 21 d ago |
| Sep 17, 2026 | SOpen-market sale Common Shares | -13,679 | $57.09 | $781k | 16,637 | 21 d ago |
| Sep 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -30,000 | $0.00 | $0 | 0 | 21 d ago |
Related signals
Other insiders at CRISPR Therapeutics AG and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $119k 1,990 shares | -2% | |
| 8Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $626k 10,400 shares | -10% | |
| 21Weak | CRSPsell CRISPR Therapeutics AG | Naimish Patel Chief Medical Officer | $141k 3,932 shares | -39% | |
| 33Weak | CRISPR Therapeutics AG | Julianne Bruno Chief Operating Officer | $71k 1,714 shares | -14% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $131k 3,185 shares | -4% | |
| 36Weak | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $91k 2,197 shares | -12% | |
| 41Moderate | CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $414k 10,031 shares | -5% | |
| 38Weak | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $157k 3,762 shares | -23% | |
| 32Weak | CRISPR Therapeutics AG | Julianne Bruno Chief Operating Officer | $59k 1,388 shares | -15% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $169k 3,966 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.